User login
- /content/ibrutinib-discontinuation-harms-survival-cll
- /hematologynews/article/177618/cll/ibrutinib-discontinuation-harms-survival-cll
- /jcso/article/177618/cll/ibrutinib-discontinuation-harms-survival-cll
- /oncologypractice/article/177618/cll/ibrutinib-discontinuation-harms-survival-cll
- /hematologynews/nhlhub/article/177618/cll/ibrutinib-discontinuation-harms-survival-cll
- /hematology-oncology/article/177618/cll/ibrutinib-discontinuation-harms-survival-cll
- /b-cell-lymphoma-icymi/article/177618/cll/ibrutinib-discontinuation-harms-survival-cll